| Literature DB >> 29272498 |
Zhengping Huang1, Changhai Ding1,2,3, Tianwang Li1, Shirley Pei-Chun Yu4.
Abstract
OA is a chronic, progressive and disabling joint disease, leading to a poor quality of life and an enormous social and economic burden. Current therapies for OA patients remain limited, which creates an area of huge unmet medical need. For some time, researchers have been looking for approaches that can inhibit the structural progression of OA. A variety of potential disease-modifying OA drugs have been developed, targeting cartilage, inflammatory pathways or subchondral bone. In addition, non-pharmacological therapies, including joint distraction and weight loss, draw increasing attention, with some showing disease-modifying potential. Thus we performed a comprehensive review to discuss the current status of disease-modifying therapies in OA and appraise the potentials of emerging novel agents.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29272498 DOI: 10.1093/rheumatology/kex496
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580